Alzheimers and Dementia amyotrophic lateral sclerosis Biotechnology

New drug therapy could improve brain function and life expectancy of ALS patients

Ben-Gurion University of the Negev (BGU) researchers are developing a new therapy for Amyotrophic Lateral Sclerosis (ALS) using part of an existing FDA-approved drug that restores the central nervous system's (CNS) immune defenses and increases life expectancy. ALS, also known as Lou Gehrig's disease, is a lethal, progressive neurodegenerative disorder that affects the motor nerve cells in both the brain and the spinal cord. The progressive degeneration of motor neurons
amyotrophic lateral sclerosis Pharmaceuticals

FDA approves drug to treat ALS

The U.S. Food and Drug Administration approved Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease. “After learning about the use of edaravone to treat ALS in Japan, we rapidly engaged with the drug developer about filing a marketing application in the United States,” said Eric Bastings, M.D., deputy director of the Division of Neurology Products in the FDA’s Center for Drug